Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.42 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259268 | 1.00 | SOAT2 (0.45) | SOAT2SOAT1EPHX2FAAHLPAR1 | |
| SCHEMBL10718160 | 0.84 | TSHR (0.40) | ALDH1A1PPARG | |
| SCHEMBL1259269 | 0.78 | SOAT2 (0.53) | SOAT2SOAT1EPHX2FAAHCNR1 | |
| SCHEMBL29033402 | 0.76 | TSHR (0.44) | ALDH1A1PPARG | |
| SCHEMBL4733273 | 0.76 | LMNA (0.46) | ALDH1A1 | |
| Phosphine SCHEMBL28650212 | 0.74 | LTA4H (0.43) | ALDH1A1PPARG | |
| SCHEMBL15859351 | 0.74 | LTA4H (0.66) | FAAHCNR1PPARAALDH1A1 | |
| SCHEMBL15859352 | 0.74 | LTA4H (0.66) | FAAHCNR1PPARAALDH1A1 | |
| SCHEMBL25208892 | 0.74 | P2RY10 (0.47) | SOAT2SOAT1LPAR1LPAR3 | |
| SCHEMBL2217525 | 0.74 | P2RY10 (0.47) | SOAT2SOAT1LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092739-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIMA THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893302-B2 | novel cationic lipids based on 4-(aminomethyl)-1,2-bis-(fatty ether or ester)-benzene | SIRNA THERAPEUTICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100105933-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | CHEN TONGQIAN | 2010-04-29 | — | — | US | disclosed |
| US-7691405-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100063308-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | BANK OF AMERICA, N.A. | 2010-03-11 | — | — | US | disclosed |
| US-20100048888-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIRNA THERAPEUTICS, INC., A WHOLLY OWNED SUBSIDIARY OF MERCK & CO., INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | MERCK SHARP & DOHME CORP. | 2010-01-21 | — | — | US | disclosed |
| US-7641915-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC (US) | 2010-01-05 | — | — | US | disclosed |
| EP-2131848-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | Merck & Co., Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| EP-2104740-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | Sirna Therapeutics, Inc. (US) | 2009-09-30 | — | — | EP | disclosed |
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | SIRNA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| WO-2008147438-A2 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008103276-A2 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALY ACTIVE MOLECULES | MERCK & CO., INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | SIRNA THERAPEUTICS INC. (US) | 2008-08-07 | — | — | US | disclosed |
| US-7404969-B2 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1922300-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | Sirna Therapeutics Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| WO-2007086883-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007086881-A2 | CATIONIC LIPIDS AND FORMULATED MOLECULAR COMPOSITIONS CONTAINING THEM | SIRNA THERAPEUTICS, INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | SIRNA THERAPEUTICS, INC. (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092739-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | SOAT2 1131/4885SOAT1 769/4885EPHX2 873/4885 |
| US-20090048197-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | SOAT2 1249/4885SOAT1 784/4885EPHX2 929/4885 |
| US-20100048888-A1 | Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules | PHAX, CETP, LIPC | SOAT2 1249/4885SOAT1 784/4885EPHX2 929/4885 |
| US-20100063308-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | SOAT2 1131/4885SOAT1 769/4885EPHX2 873/4885 |
| US-20060240554-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | SOAT2 1131/4885SOAT1 769/4885EPHX2 873/4885 |
| US-20080020058-A1 | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules | PHAX, CETP, LIPC | SOAT2 1249/4885SOAT1 784/4885EPHX2 929/4885 |
| US-20100105933-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | SOAT2 1249/4885SOAT1 784/4885EPHX2 929/4885 |
| US-20100015218-A1 | COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, MTREX, CHIA | SOAT2 1270/4885SOAT1 988/4885EPHX2 879/4885 |
| US-20080188675-A1 | LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | PHAX, CETP, LIPC | SOAT2 1131/4885SOAT1 769/4885EPHX2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.